We and other groups have previously found that the key transcription factor of the SHH pathway, GLI1, is upregulated and serves as a therapeutic target in lung cancer specimens; however, genetic alterations were rarely detected [6, 7, 9]. This evidence concerns the gene GLI1 and lung carcinoma.